Home / Knowledge Centre /
Poster

Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma

Download the following Poster Presentation: Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma.

Conclusions:

The DDRD assay:
1. Is the first gene expression biomarker to utilise FFPE tissue in oesophago-gastric cancer.
2. Demonstrates a strong association with prognosis in:

  • EAC patients treated with neo-adjuvant chemotherapy
  • GC patients treated with surgery + adjuvant chemo/chemoXRT

3. Predicts Pathological Response to neo-adjuvant chemotherapy
4. Could personalise treatment approaches in oesophago-gastric cancer.

View Resource

Download here instantly

You may also be interested in

Managing Biomarker/Companion Diagnostic (CDx) Programs with Pharma: A Diagnostic Company’s Perspective
Webinar

Managing Biomarker/Companion Diagnostic (CDx) Programs with Pharma: A Diagnostic Company’s Perspective

Overcoming EU IVDR Challenges When Using Clinical Trial Assays to Accelerate Global CDx Trials
Webinar

Overcoming EU IVDR Challenges When Using Clinical Trial Assays to Accelerate Global CDx Trials

Stay up-to-date with the latest from Almac

Join our mailing list
This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies